Validation of an instrument for screening cases of type 2 diabetes and monitoring at-risk individuals in Mexico;Validación de un instrumento para el tamizaje de casos de diabetes tipo 2 y la vigilancia de personas en riesgo en México

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 27, Issue 3, 2010, Pages 181-186

  Guerrero Romero, Fernando ^a   Rodríguez Morán, Martha ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Diabetes mellitus; Mass screening; Mexico; Monitoring; Risk factors; Type 2

Indexed keywords

COHORT ANALYSIS; COMMUNITY STRUCTURE; DIABETES; DISEASE PREVALENCE; HEALTH MONITORING; HEALTH POLICY; HEALTH RISK; REGRESSION ANALYSIS; RISK FACTOR;

MEXICO [MEXICO (NTN)]; MEXICO [NORTH AMERICA];

EID: 77951203320     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/S1020-49892010000300005     Document Type: Article

References (26)

1. Wild S, Roglic G, Sicree R, Green A, King H. Global burden of diabetes mellitus in the year 2000. Global burden of disease. Geneva: World Health Organization; 2003.
2. Nathan DM, Herman WH. Screening for diabetes: can we afford not to screen? Ann Intern Med. 2004;140(9):756-758
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053
4. Thompson WG. Early recognition and treatment of glucose abnormalities to prevent type 2 diabetes mellitus and coronary heart disease. Mayo Clin Proc. 2001;76(11):1137-1143
5. The CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. J Am Med Assoc. 1998; 280(20):1757-1763
6. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ. Impact of diabetes screening on quality of life. Diabetes Care. 2002;25(6):1022-1026
7. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med. 2004(9);140:689-699
8. U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: recommendations and rationale. Ann Intern Med. 2003;138(3):215-229
9. Norris SL, Kansagara D, Bougatsos CH, Fu R. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2008; 148(11):855-868
10. Engelgau MM, Narayan KMV, Herman WH. Screening for type 2 diabetes. Diabetes Care. 2002,23(9):1563-1580
11. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. Br Med J. 2008;336(7654):1180-1185
12. Lawrence JM, Bennett P, Young A, Robinson AM. Screening for diabetes in general practice: cross sectional population study. Br Med J. 2001;323(7312):548-551
13. Rodríguez-Morán M, Alvarado-Ruiz R, Morales-Franco G, Guerrero-Romero F. Combinación de un cuestionario autoaplicable con la determinación de glucosa capilar en el tamizaje de diabetes tipo 2. Salud Publica Mex. 2008;50(4):272.
14. Heikes KE, Eddy DM, Arondekar B, Schlessinger L. Diabetes risk calculator. A simple tool for detecting undiagnosed diabetes and pre-diabetes. Diabetes Care. 2008; 31(5):1040-1045
15. Franciosi M, De Berardis G, Rossi MC, Sacco M, Belfiglio M, Pellegrini F, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care. 2005;28(5):1187-1194
16. Ealovega MW, Tabaei BP, Brandle M, Burke R, Herman WH. Opportunistic screening for diabetes in routine clinical practice. Diabetes Care. 2004;27(1):9-12.
17. Breiman L, Friedman J, Olshen RA, Stone CJ. Classification and regression trees. Boca Raton, FL: Chapman and Hall/CRC; 1998.
18. Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Llanne-Parikka P, et al. Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia. 1999;42(7):793-801.
19. Kramer MS. Clinical epidemiology and biostatistics. A primer for investigators and decision-makers. Berlin: Springer-Verlag; 1988:201-210
20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28(Suppl 1):S37-42.
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-1252
22. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003;26(Suppl 1):S5-20.
23. Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metab. 2007;92(5):1581-1589
24. American Diabetes Association. Screening for diabetes. Diabetes Care. 2003;26(Suppl. 1): S21-4.
25. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. Diabetes. 1998; 47(5):699-713.
26. Kahn HS, Cheng YJ, Thompson TJ, Imperatore G, Gregg EW. Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years. Ann Intern Med. 2009;150(11):741-751